MK-2866 (Ostarine)

Description

Product Description

Dosage and Formulation:
This product is supplied in a 50 ml volume with a concentration of 25 mg/ml. Each 50 ml contains a total of 1,250 mg (50 x 25 mg) of the active ingredient.

Chemical Properties:
– Molecular Weight: 441.36 g/mol
– Chemical Formula: C₁₉H₁₈F₃N₃O₆

Solubility:
The product demonstrates good solubility in polyglycols, making it suitable for various applications that require a specific solvent medium.

Purity:
This formulation boasts a purity of over 99%, ensuring high quality and efficacy for its intended use.

Storage Conditions:
For optimal stability, store at a controlled temperature of 20℃. The product is shelf-stable for a period of 2 years from the date of manufacture.

Pharmacokinetics:
– Half-Life: The average half-life of the compound is 4 hours, which is an important consideration for dosing schedules in clinical or laboratory settings.

CAS Number:
The unique Chemical Abstracts Service (CAS) number for this compound is 401900-40-1, which can be used for identification and reference in scientific literature and databases.

Modification Date:
The information provided was last modified on February 1st, 2024.

This product is designed for use in specific applications where its solubility, stability, and purity levels will be beneficial. Always consult with a professional for further guidance regarding usage and safety protocols.

Si noti che l’ingrediente principale di cui stai cercando riferimenti scientifici sembra essere il SARMs (Selective Androgen Receptor Modulators) chiamato Andarine o S4, che ha come numero CAS 401900-40-1. Ecco alcuni riferimenti scientifici per l’Andarine:

1. Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. Journal of Cachexia, Sarcopenia and Muscle. 2011;2(3):153‐161. Link
2. Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today. 2007;12(5-6):241‐248.Link
3. Kearbey JD, Gao W, Narayanan R, et al. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res. 2007;24(2):328‐335. Link
4. Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87‐95. Link